- Trial phase
- Phase 1
- Time to market
- If MGC028 advances successfully through Phase 1 dose optimization and into Phase 2/3 trials, potential approval would be several years away, likely 2029 or later under an optimistic scenario. The drug is currently in Phase 1 dose optimization.
- Why 3/10
- MGC028 is a Phase 1 ADC with no scheduled hard binary catalyst (PDUFA, pivotal readout, or AdComm) in the next 12 months. The Phase 1 dose escalation recently completed and interim results were presented at ESMO 2026. The next milestone is maturation of the ongoing dose optimization cohort(s), with no specified date. MGC028 is one of several preclinical/Phase 1 assets at MacroGenics and is not the company's lead program. Per the rubric, a Phase 1 asset with no scheduled binary catalyst scores below 5.
MGC028 is now in dose optimization after completing Phase 1 dose escalation. The next data readout could come in 2027 once both dose-level cohorts mature, but no date is set. Interim results were already presented at ESMO 2026; the market reaction to those data was not a major stock mover since MGC028 is one of several early-stage assets at MacroGenics. Watch for any future clinical update or partnership interest around the ADAM9 target.
Price Chart
Executive Summary
MGC028 is an early-stage antibody-drug conjugate (ADC) targeting ADAM9, a protein overexpressed in several cancers, being developed by MacroGenics (NASDAQ: MGNX). It uses a Topoisomerase 1 inhibitor payload, the same drug class used in several approved ADCs. As of November 2026, the Phase 1 first-in-human dose-escalation study has been completed and interim results were presented at ESMO 2026. The company selected a lead indication and is now performing dose optimization across two dose levels. MGC028 is one of several pipeline programs at MacroGenics, which also includes MGC026 (B7-H3 ADC, mid-2027 update), MGC030 (Phase 1 just started), and lorigerlimab (Phase 2). With no approved products, MacroGenics trades at approximately $2.20 per share with a ~$148M market cap, below its $287M cash position, implying the pipeline has negative enterprise value. No hard binary catalyst is scheduled for MGC028 in the next 12 months.
How It Works
MGC028 is an antibody-drug conjugate (ADC), a type of precision cancer therapy. It works like a guided missile: the antibody portion targets a protein called ADAM9 found on the surface of many cancer cells (including pancreatic, lung, and gastric cancers). When the antibody binds to ADAM9, the cancer cell internalizes the drug, and a chemotherapy payload (a Topoisomerase 1 inhibitor) is released inside the cell to kill it. The Topo1 inhibitor class is the same mechanism used in several approved ADCs including Enhertu and Trodelvy.
Trial Status
Phase 1 first-in-human dose escalation completed. Interim results presented at ESMO 2026. Selected lead indication for dose optimization across two dose levels. No specific next-readout date has been announced.
The Two-Sided Case
Upcoming Catalysts
- Updated Phase 1 dose optimization data (timing unspecified)
- Possible selection of a specific tumor indication for Phase 2 expansion
- Broader MacroGenics catalysts: MGC026 data update mid-2027, MGC030 Phase 1 enrollment updates, lorigerlimab Phase 2 CCGC update H1 2027
Source Filing
The SecBot filing or press-release report that triggered this drug report:
MacroGenics, Inc. PRESS-RELEASE MGNX ·Originating report